- $1.65bn
- $1.60bn
- $465.31m
- 81
- 33
- 99
- 82
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.59 | ||
| Price to Tang. Book | 9.74 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 3.55 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -7.72% | ||
| Return on Equity | -9.64% | ||
| Operating Margin | -8.89% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 206.53 | 274.33 | 330.38 | 399.25 | 465.31 | 522.79 | 588.54 | 15.05% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
AtriCure, Inc. provides technologies for the treatment for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management. The Company's cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Its pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures. The Company's products for open and minimally invasive ablation include Isolator Synergy Clamps and Multifunctional Pens and Linear Ablation Devices. Its products for open ablation include cryoICE Cryoablation System. Its products for minimally invasive ablation include EPi-Sense Guided Coagulation System with VisiTrax Technology. Its appendage management products include AtriClip System. The Isolator Synergy Ablation System clamps are single-use disposable radio frequency (RF) products with jaws that close in a parallel fashion.
Directors
- B. Kristine Johnson NEC (69)
- Michael Carrel PRE (50)
- Angela Wirick CFO (43)
- Douglas Seith COO (55)
- Salvatore Privitera CTO (54)
- Justin Noznesky CMO (43)
- Deborah Telman DRC
- Maggie Yuen DRC (49)
- Mark Collar IND (68)
- Daniel Florin IND (57)
- Regina Groves IND (62)
- Karen Prange IND (57)
- Sven Wehrwein IND (70)
- Robert White IND
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 31st, 2000
- Public Since
- August 5th, 2005
- No. of Shareholders
- 59
- No. of Employees
- 1,300
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 49,493,902
- Address
- 7555 Innovation Way, MASON, 45040
- Web
- https://www.atricure.com
- Phone
- +1 5137554100
- Auditors
- Deloitte & Touche LLP
Upcoming Events for ATRC
Q1 2025 AtriCure Inc Earnings Call
AtriCure Inc Annual Shareholders Meeting
AtriCure Inc Annual Shareholders Meeting
Q2 2025 AtriCure Inc Earnings Release
Q3 2025 AtriCure Inc Earnings Release
Similar to ATRC
908 Devices
NASDAQ Global Market
Alpha Teknova
NASDAQ Global Market
Anteris Technologies Global
NASDAQ Global Market
Beta Bionics
NASDAQ Global Market
Brainsway
NASDAQ Global Market
FAQ
What is the AtriCure share price?
As of Today at 19:25 UTC, shares in AtriCure are trading at $33.40. This share price information is delayed by 15 minutes.
How has the AtriCure share price performed this year?
Shares in AtriCure last closed at $33.40 and the price had moved by +47.72% over the past 365 days. In terms of relative price strength the AtriCure share price has outperformed the S&P500 Index by +36.35% over the past year.
What are the analyst and broker recommendations for AtriCure?
The overall consensus recommendation for AtriCure is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the AtriCure dividend yield?
AtriCure does not currently pay a dividend.
Does AtriCure pay a dividend?
AtriCure does not currently pay a dividend.
When does AtriCure next pay dividends?
AtriCure does not currently pay a dividend.
How do I buy AtriCure shares?
To buy shares in AtriCure you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of AtriCure?
As of the previous close price of $33.40, shares in AtriCure had a market capitalisation of $1.65bn.
Where are AtriCure shares listed?
Here are the trading details for AtriCure:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: ATRC
What kind of share is AtriCure?
Based on an overall assessment of its quality, value and momentum AtriCure is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a AtriCure share price forecast for 2025?
The analyst consensus target price for shares in AtriCure is $53.00. That is 58.68% above the last closing price of $33.40.
Analysts covering AtriCure currently have a consensus Earnings Per Share (EPS) forecast of -$0.66 for the next financial year.
Find out moreWhat is the trend in the AtriCure share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like AtriCure. Over the past six months, its share price has outperformed the S&P500 Index by +26.04%.
As of the last closing price of $33.40, shares in AtriCure were trading +5.85% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the AtriCure PE Ratio?
The AtriCure PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $33.40.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of AtriCure?
AtriCure's management team is headed by:
- B. Kristine Johnson - NEC
- Michael Carrel - PRE
- Angela Wirick - CFO
- Douglas Seith - COO
- Salvatore Privitera - CTO
- Justin Noznesky - CMO
- Deborah Telman - DRC
- Maggie Yuen - DRC
- Mark Collar - IND
- Daniel Florin - IND
- Regina Groves - IND
- Karen Prange - IND
- Sven Wehrwein - IND
- Robert White - IND